The Lynx Group
Cholangiocarcinoma News

TreeTopp: Phase 2 Study of Varlitinib plus Capecitabine versus Placebo as Second-Line Therapy for Patients with Advanced or Metastatic Biliary Tract Cancer

August 2020, Vol 1, No 1

Varlitinib is a reversible small-molecule, pan-human epidermal growth factor receptor (HER) inhibitor with low nanomolar potency against HER1 (EGFR), HER2, and HER4.

The global, multicenter, double-blind, phase 2 TreeTopp study included patients with biliary tract cancer whose disease progressed after receiving first-line therapy that included ≥6 doses of gemcitabine, and had radiographically measurable disease based on RECIST version 1.1 criteria, Eastern Cooperative Oncology Group performance status 0 or 1, and albumin ≥3 g/dL.1

The study’s results were reported by Milind M. Javle, MD, Professor, Department of Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, Houston, TX, and colleagues, in a poster at the 2020 ASCO annual meeting.

The study patients were randomized (1:1) to varlitinib 300 mg twice daily plus capecitabine 1000 mg/m2 twice daily, given in a schedule of 14 days on and 7 days off, or to placebo plus capecitabine.

The dual primary end points were objective response rate (ORR) and progression-free survival (PFS), defined as the time from randomization to radiologic progression assessed by independent central review. A secondary end point was overall survival (OS).

The study randomized 127 patients, including 64 patients who received varlitinib plus capecitabine and 63 patients who received placebo plus capecitabine.

The ORR was 9.4% with varlitinib plus capecitabine versus 4.8% with placebo plus capecitabine (odds ratio, 2.278; P = .42). The median PFS was the same for patients who received varlitinib plus capecitabine and for those who received placebo plus capecitabine, at 2.8 months (hazard ratio [HR], 0.9; P = .63). The median OS was 7.8 months with varlitinib plus capecitabine versus 7.5 months with placebo plus capecitabine (HR, 1.11; P = .66).

Although this study was not powered to evaluate subgroup interactions, in a subgroup analysis, varlitinib plus capecitabine showed PFS benefit versus placebo plus capecitabine in the subgroup of patients with gallbladder cancer (median PFS, 2.9 months vs 1.6 months; HR, 0.55), and among female patients (median PFS, 4.1 months vs 2.8 months; HR, 0.59).

There was no PFS benefit for varlitinib plus capecitabine compared with placebo plus capecitabine among male patients and in patients without gallbladder cancer.

The adverse events were generally balanced between the study arms, apart from a slightly higher incidence of hyperbilirubinemia, diarrhea, and fatigue in the varlitinib plus capecitabine arm versus the placebo plus capecitabine arm. Grade 3 or 4 toxicities were reported in 66% and 59% of patients in the varlitinib plus capecitabine and placebo plus capecitabine arms, respectively.

Based on the interim data as of July 15, 2019, the investigators concluded that although no benefit was found with varlitinib plus capecitabine in terms of ORR, PFS, or OS versus placebo plus capecitabine in the second-line treatment of advanced biliary tract cancer, a subgroup analysis suggested that patients with gallbladder cancer and female patients achieved a comparatively higher median PFS with varlitinib plus capecitabine therapy compared with placebo plus capecitabine.

Reference

  1. Javle MM, Oh DY, Ikeda M, et al. Results from TreeTopp: a randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC). J Clin Oncol. 2020;38(15_suppl):Abstract 4597.

Related Items

Hot Topics on Cholangiocarcinoma and Biliary Tract Cancer Presented at ASCO 2020
By Milind Javle, MD
August 2020, Vol 1, No 1
Several hot topics were presented at the recent ASCO 2020 annual meeting about cholangiocarcinoma (CCA), which I would briefly discuss here. First, it was very exciting to see 3 important studies regarding immunotherapy for CCA, which may represent a step forward in the development of CCA therapies.
Assessing the Safety, Efficacy, and Biomarkers of Durvalumab in Chemotherapy-Naïve Patients with Advanced Biliary Tract Cancer
August 2020, Vol 1, No 1
Immunotherapies have shown early promising efficacy in some patients with biliary tract cancer. Investigators evaluated the benefit of durvalumab (Imfinzi), a PD-L1 inhibitor, with or without tremelimumab, a CTLA-4 inhibitor, plus chemotherapy with gemcitabine and cisplatin as a first-line treatment for Korean patients with biliary tract cancer. The researchers also performed an extensive biomarker analysis.
Combination Immunotherapy with Ipilimumab and Nivolumab Shows Activity in Patients with Advanced Biliary Tract Cancer
August 2020, Vol 1, No 1
The combination of a CTLA-4 inhibitor and a PD-1 inhibitor with ipilimumab (Yervoy) and nivolumab (Opdivo) has demonstrated superior efficacy compared with single-agent anti–PD-1 therapy in a previous study of patients with advanced melanoma and renal-cell carcinoma.
Nivolumab with Chemotherapy or with Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
August 2020, Vol 1, No 1
Arandomized, phase 2 multi-institutional study compared the role of combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) versus nivolumab plus chemotherapy with gemcitabine and cisplatin in the first-line treatment of patients with advanced biliary tract cancer.
Retrospective Analysis of Post–Second-Line Chemotherapy Outcomes in Patients with Advanced or Metastatic CCA and FGFR2 Fusions
August 2020, Vol 1, No 1
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy, with an estimated incidence of 8000 to 10,000 patients annually in the United States. Chemotherapy is the most common second-line treatment with response rates of <10% and median progression-free survival (PFS) of approximately 3 to 4 months, including FOLFOX in the ABC-06 trial. Fibroblast growth factor receptor (FGFR) 2 fusions occur in 13% to 17% of patients with CCA, and multiple targeted agents are in development for patients with FGFR2 fusions. To date, the outcome of patients with CCA and FGFR2 fusions who receive standard second-line chemotherapy is unknown.
Natural History of Cholangiocarcinoma with FGFR Alterations
August 2020, Vol 1, No 1
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are emerging as promising therapeutic targets in patients with cholangiocarcinoma (CCA). A retrospective chart review, led by Lipika Goyal, MD, MPhil, Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, was performed in patients with CCA who had an FGFR alteration found by tumor molecular profiling as part of routine care.1 Dr Goyal presented this study at the 2020 ASCO annual meeting.
FOENIX-CCA2: Phase 2 Open-Label Study of Futibatinib in Patients with Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions
August 2020, Vol 1, No 1
Futibatinib is a highly selective irreversible fibroblast growth factor receptor (FGFR)1-4 inhibitor, administered as a continuous once-daily oral regimen. The FOENIX-CCA2 phase 2 clinical trial was initiated after the results from a phase 1 dose-escalation/expansion study showed the tolerability and preliminary efficacy of futibatinib in patients with intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions.
Phase 2 Study of Modified FOLFOX versus Modified FOLFIRI in Patients with Locally Advanced or Metastatic Biliary Tract Cancer Refractory to First-Line Chemotherapy
August 2020, Vol 1, No 1
In patients with locally advanced or metastatic biliary tract cancer, treatment with second-line chemotherapy is challenging after disease progression from first-line gemcitabine plus cisplatin, although treatment with modified FOLFOX (mFOLFOX) has been proven to be superior to active symptom control in the ABC-06 trial. Irinotecan (Camptosar) is an active drug used in the treatment of various gastrointestinal cancers.
ClarIDHy Phase 3 Study: IDH1 Mutation Detection in ctDNA and Clinical Response in Patients with Advanced Intrahepatic Cholangiocarcinoma
August 2020, Vol 1, No 1
Mutations in IDH1 are detected in approximately 13% of patients with intrahepatic cholangiocarcinoma (CCA). ClarIDHy was a global, phase 3, double-blind clinical trial in previously treated patients with advanced intrahepatic CCA with IDH1 mutation.
Comparing Primary Tumor, Metastatic Tumor Tissue, and Liquid Biopsy in Intrahepatic Cholangiocarcinoma: Comprehensive Genomic Profiling Study
August 2020, Vol 1, No 1
Genomic alterations that are characteristic of intrahepatic cholangiocarcinoma (CCA) are well known. A study led by Jeffrey S. Ross, MD, Medical Director, Foundation Medicine, Cambridge, MA, examined whether genomic alterations from a primary tumor would differ from metastatic tumor tissue and liquid biopsy in patients with intrahepatic CCA. The study results were presented at the 2020 ASCO annual meeting.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: